PT-141 Specification and Vial Format Review walks through PT-141 (10mg) documentation, vial format, and buyer workflow for Neuropeptide Research laboratories using sulanpeptide.vip.
PT-141, also known as Bremelanotide, is a melanocortin receptor agonist peptide used in laboratory research on melanocortin pathway signaling, receptor activation, and neuropeptide structure-activity studies.
MC4R cAMP assays, hypothalamic neuron calcium imaging, and receptor autoradiography map CNS melanocortin engagement in preclinical models. Melanocortin pharmacology literature distinguishes peripheral versus central receptor targets when interpreting peptide agonist selectivity profiles.
PT-141 (bremelanotide) activates melanocortin MC3R and MC4R receptors studied in central nervous system slice preparations and receptor selectivity panels. Cyclic heptapeptide structure derived from melanotan scaffold research underpins receptor pharmacology studies.
Side-by-side review of specification table, vial label, and COA prevents release errors for PT-141. Principal investigators should sign off PT-141 SKUs only after mechanism fit is documented in the study protocol.
Spec alignment: Enter exact strength notation (10mg) in procurement systems—do not round kit counts.
Catalog identifiers for PT-141: CAS 189691-06-3, Formula: C50H68N14O10. MW 1025.2 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for PT-141 to support reproducibility.
Dose planning for PT-141 should state mass (10mg) or molarity derived from catalog molecular weight.
Molecular identifiers for PT-141—CAS 189691-06-3, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing PT-141 should include these fields for reproducibility in Neuropeptide Research journals. Format selection for PT-141 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for PT-141. QA sign-off should reference all four documents in the batch record. Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for PT-141 should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type.
Specification alignment for PT-141 requires copying exact kit notation (10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for PT-141 should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type. Specification alignment for PT-141 requires copying exact kit notation (10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for PT-141. QA sign-off should reference all four documents in the batch record.
Specification alignment for PT-141 requires copying exact kit notation (10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits. Molecular identifiers for PT-141—CAS 189691-06-3, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing PT-141 should include these fields for reproducibility in Neuropeptide Research journals.
Format selection for PT-141 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for PT-141. QA sign-off should reference all four documents in the batch record.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for PT-141 should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type.
PT-141 from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.